## Lee S Newman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11734351/publications.pdf

Version: 2024-02-01

66 papers 6,418 citations

94433 37 h-index 60 g-index

70 all docs

70 docs citations

times ranked

70

3301 citing authors

#	Article	IF	CITATIONS
1	CpG promoter methylation status is not a prognostic indicator of gene expression in beryllium challenge. Journal of Immunotoxicology, 2016, 13, 417-427.	1.7	1
2	Accelerator mass spectrometry detection of beryllium ions in the antigen processing and presentation pathway. Journal of Immunotoxicology, 2015, 12, 181-187.	1.7	1
3	Birth Outcomes and Natural Gas Development: McKenzie et al. Respond. Environmental Health Perspectives, 2014, 122, A232-3.	6.0	14
4	Birth Outcomes and Maternal Residential Proximity to Natural Gas Development in Rural Colorado. Environmental Health Perspectives, 2014, 122, 412-417.	6.0	275
5	The Use of Health Impact Assessment for a Community Undergoing Natural Gas Development. American Journal of Public Health, 2013, 103, 1002-1010.	2.7	52
6	Human health risk assessment of air emissions from development of unconventional natural gas resources. Science of the Total Environment, 2012, 424, 79-87.	8.0	472
7	Beryllium-specific CD4+ T cells in blood as a biomarker of disease progression. Journal of Allergy and Clinical Immunology, 2011, 128, 1100-1106.e5.	2.9	26
8	Risk of Chronic Beryllium Disease by HLA-DPB1 E69 Genotype and Beryllium Exposure in Nuclear Workers. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1680-1688.	5.6	43
9	Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry. Occupational and Environmental Medicine, 2011, 68, 842-848.	2.8	29
10	Mycobacterial ESAT-6 and katG are Recognized by Sarcoidosis CD4+ T Cells When Presented by the American Sarcoidosis Susceptibility Allele, DRB1*1101. Journal of Clinical Immunology, 2010, 30, 157-166.	3.8	56
11	Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Human Molecular Genetics, 2010, 19, 4100-4111.	2.9	121
12	Sulfasalazine and Mesalamine Modulate Beryllium-Specific Lymphocyte Proliferation and Inflammatory Cytokine Production. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 458-464.	2.9	6
13	Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease. American Journal of Industrial Medicine, 2009, 52, 762-773.	2.1	31
14	Occupational Interstitial Lung Disease Update. , 2009, , 195-211.		0
15	TGF- $\hat{l}^21$ Variants in Chronic Beryllium Disease and Sarcoidosis. Journal of Immunology, 2007, 179, 4255-4262.	0.8	47
16	Beryllium-Induced TNF-α Production Is Transcription-Dependent in Chronic Beryllium Disease. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 191-200.	2.9	14
17	Gene-environment interactions in sarcoidosis: challenge and opportunity. Clinics in Dermatology, 2007, 25, 267-275.	1.6	43
18	Comparison of Sarcoidosis Phenotypes Among Affected African-American Siblings. Chest, 2006, 130, 855-862.	0.8	43

#	Article	IF	Citations
19	Mycobacterial antigens may be important in sarcoidosis pathogenesis. Current Opinion in Pulmonary Medicine, 2006, 12, 359-363.	2.6	66
20	Secondary Ion Mass Spectroscopy Demonstrates Retention of Beryllium in Chronic Beryllium Disease Granulomas. Journal of Occupational and Environmental Medicine, 2005, 47, 1218-1226.	1.7	31
21	Beryllium Sensitization Progresses to Chronic Beryllium Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 54-60.	5.6	157
22	Lung Fibrosis in Plutonium Workers. Radiation Research, 2005, 164, 123-131.	1.5	28
23	Frequency of beryllium-specific, T1-type cytokine-expressing CD4 T cells in patients with beryllium-induced disease. Journal of Allergy and Clinical Immunology, 2005, 115, 1036-1042.	2.9	42
24	Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response. Journal of Clinical Investigation, 2005, 115, 2886-2893.	8.2	52
25	Beryllium-Ferritin. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 470-477.	2.9	31
26	Beryllium-Induced Tumor Necrosis Factor-α Production by CD4+T Cells Is Mediated by HLA-DP. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 122-130.	2.9	35
27	A Case Control Etiologic Study of Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1324-1330.	5.6	612
28	Occupational interstitial lung disease. Clinics in Chest Medicine, 2004, 25, 467-478.	2.1	49
29	Beryllium exposure and chronic beryllium disease. Lancet, The, 2004, 363, 415-416.	13.7	82
30	Beryllium Medical Surveillance at a Former Nuclear Weapons Facility During Cleanup Operations. Journal of Occupational and Environmental Medicine, 2004, 46, 953-961.	1.7	32
31	Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease. American Journal of Industrial Medicine, 2003, 43, 592-601.	2.1	16
32	Identification of an abnormal beryllium lymphocyte proliferation test. Toxicology, 2003, 183, 39-56.	4.2	37
33	HLA-DRB1*1101: A Significant Risk Factor for Sarcoidosis in Blacks and Whites. American Journal of Human Genetics, 2003, 73, 720-735.	6.2	342
34	CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells. Journal of Clinical Investigation, 2003, 112, 776-784.	8.2	45
35	CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells. Journal of Clinical Investigation, 2003, 112, 776-784.	8.2	31
36	Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2003, 20, 204-11.	0.2	122

#	Article	IF	Citations
37	Beryllium Skin Patch Testing to Analyze T Cell Stimulation and Granulomatous Inflammation in the Lung. Journal of Immunology, 2002, 168, 3627-3634.	0.8	41
38	Chronic beryllium disease: a model interaction between innate and acquired immunity. International Immunopharmacology, 2002, 2, 249-261.	3.8	42
39	Target organ localization of memory CD4+ T cells in patients with chronic beryllium disease. Journal of Clinical Investigation, 2002, 110, 1473-1482.	8.2	82
40	Target organ localization of memory CD4+ T cells in patients with chronic beryllium disease. Journal of Clinical Investigation, 2002, 110, 1473-1482.	8.2	57
41	Chronic Beryllium Disease: T Cell Recognition of a Metal Presented by HLA-DP. Clinical Immunology, 2001, 100, 4-14.	3.2	56
42	Efficacy of Serial Medical Surveillance for Chronic Beryllium Disease in a Beryllium Machining Plant. Journal of Occupational and Environmental Medicine, 2001, 43, 231-237.	1.7	73
43	Beryllium Particulate Exposure and Disease Relations in a Beryllium Machining Plant. Journal of Occupational and Environmental Medicine, 2001, 43, 238-249.	1.7	80
44	Beryllium sensitivity is linked to HLA-DP genotype. Toxicology, 2001, 165, 27-38.	4.2	70
45	Inorganic Dust Pneumonias: The Metal-Related Parenchymal Disorders. Environmental Health Perspectives, 2000, 108, 685.	6.0	51
46	Aerosols Generated During Beryllium Machining. Journal of Occupational and Environmental Medicine, 2000, 42, 8.	1.7	39
47	Beryllium-stimulated in vitro migration of peripheral blood lymphocytes. Toxicology, 1999, 138, 155-163.	4.2	15
48	Expansions of T-cell Subsets Expressing Particular T-cell Receptor Variable Regions in Chronic Beryllium Disease. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 581-589.	2.9	79
49	Sarcoidosis. New England Journal of Medicine, 1997, 336, 1224-1234.	27.0	1,271
50	Serum neopterin in chronic beryllium disease., 1997, 32, 21-26.		16
51	Comparison of In Vivo and In Vitro Measures of Beryllium Sensitization. Journal of Occupational and Environmental Medicine, 1997, 39, 540-547.	1.7	33
52	The Natural History of Beryllium Sensitization and Chronic Beryllium Disease. Environmental Health Perspectives, 1996, 104, 937.	6.0	24
53	Significance of the Blood Beryllium Lymphocyte Proliferation Test. Environmental Health Perspectives, 1996, 104, 953.	6.0	27
54	Machining risk of beryllium disease and sensitization with median exposures below 2 $\frac{9}{m}$ , 1996, 30, 16-25.		174

#	Article	IF	CITATIONS
55	Immunology, Genetics, and Epidemiology of Beryllium Disease. Chest, 1996, 109, 40S-43S.	0.8	26
56	Differential expression of lymphocyte homing receptors by human memory/effector T cells in pulmonary versus cutaneous immune effector sites. European Journal of Immunology, 1994, 24, 1269-1277.	2.9	189
57	Epidemiology of Beryllium Sensitization and Disease in Nuclear Workers. The American Review of Respiratory Disease, 1993, 148, 985-991.	2.9	206
58	Early Pulmonary Physiologic Abnormalities in Beryllium Disease. The American Review of Respiratory Disease, 1993, 148, 661-666.	2.9	68
59	Nonoccupational Beryllium Disease Masquerading as Sarcoidosis: Identification by Blood Lymphocyte Proliferative Response to Beryllium. The American Review of Respiratory Disease, 1992, 145, 1212-1214.	2.9	89
60	Serum Angiotensin Converting Enzyme Activity in Chronic Beryllium Disease. The American Review of Respiratory Disease, 1992, 146, 39-42.	2.9	39
61	Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. Journal of Allergy and Clinical Immunology, 1991, 88, 54-60.	2.9	145
62	On the Differential Diagnosis of Chronic Beryllium Disease and Sarcoidosis: Reply. The American Review of Respiratory Disease, 1990, 142, 739-740.	2.9	0
63	Pathologic and Immunologic Alterations in Early Stages of Beryllium Disease: Re-examination of Disease Definition and Natural History. The American Review of Respiratory Disease, 1989, 140, 1834-1835.	2.9	O
64	Screening Blood Test Identifies Subclinical Beryllium Disease. Journal of Occupational and Environmental Medicine, 1989, 31, 603-608.	1.7	143
65	Pathologic and Immunologic Alterations in Early Stages of Beryllium Disease: Re-examination of Disease Definition and Natural History. The American Review of Respiratory Disease, 1989, 139, 1479-1486.	2.9	198
66	Human Berylliosis., 0,, 245-264.		0